Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. - Wikidata - wikimedia - TriplyDB

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

http://www.wikidata.org/entity/Q36875697

about

Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic HIV and aging: emerging research issues Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure Fractional Brownian motion and multivariate-t models for longitudinal biomedical data, with application to CD4 counts in HIV-positive patients.Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients.Initiation of antiretroviral therapy at high CD4 cell counts: does it reduce the risk of cardiovascular disease?Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy Attitudes of people in the UK with HIV who Are Antiretroviral (ART) Naïve to starting ART at high CD4 counts for potential health benefit or to prevent HIV transmission.Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC).Differentiated Human Immunodeficiency Virus RNA Monitoring in Resource-Limited Settings: An Economic Analysis Will expanded ART use reduce the burden of HIV-associated chronic lung disease?The natural history of HIV infection.Laboratory and clinical predictors of disease progression following initiation of combination therapy in HIV-infected adults in Thailand Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.When to start antiretroviral therapy: the need for an evidence base during early HIV infection Building clinical trial priorities at the University of Rwanda.Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy.Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial Morbidity and mortality according to latest CD4+ cell count among HIV positive individuals in South Africa who enrolled in project Phidisa INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy.Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study Antiretroviral Regimens and CD4/CD8 Ratio Normalization in HIV-Infected Patients during the Initial Year of Treatment: A Cohort Study The Medical Research Council (UK)/Uganda Virus Research Institute Uganda Research Unit on AIDS--'25 years of research through partnerships'.Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: when is immediate treatment optimal?Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa Incomplete adherence among treatment-experienced adults on antiretroviral therapy in Tanzania, Uganda and Zambia.Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials.

P2860

Q21133704-B0A6C39B-57B0-4DBA-8AA2-B388DC511348 Q27016011-6385BCF6-6FB6-4C73-A538-9986650AB889 Q28533767-4C8FEA1E-EEDA-402E-B143-7D4AB63409D4 Q31021008-183CC462-EFE1-4C04-9F44-8FAAC2886C8E Q31131058-AF3F8357-9988-4C48-AAFF-34C486ED27D2 Q33649200-0073E5B4-304A-493E-874F-720ABDE7C4BD Q33654668-DD1FCFCF-7EA1-425C-9FE8-421795EF0B8B Q33679501-BA31DBD4-FDDD-4EA8-B5CC-5DAAF50FA06E Q33736040-1B1B35F8-A323-47CC-B69B-C755A4A1D00C Q33737122-EA3AF7E3-2A51-4A9E-B075-EA77EAEC8EBB Q33797611-C7B6B3A2-6A7C-474F-BD28-E210F2BEC5EB Q34337675-2D902512-B306-4646-A0E4-6D198620E9A5 Q34385049-62AC9E8E-70E9-4E1F-8F70-DF505EAD0D90 Q34485916-559C756B-ECFD-427A-A63E-17C145E77EAF Q34736194-3213A8B0-1AEE-4DD0-9ABE-6971D41DD949 Q34773308-083BE8A2-A7DE-470C-8DF9-522C3CF71387 Q34894771-0AD04A74-7192-4147-90F2-37A147A99A07 Q35124860-DA715643-DB0D-4174-8ACD-080A1FD3692C Q35124897-CFECD427-6120-4231-AE95-2E80F8ADF9A4 Q35124901-CFDCB44C-E495-4A09-B990-984F2AC47A1A Q35124905-212D1007-1953-47F0-BC50-32F0E39D6F45 Q35124913-F0989856-CD17-43D3-B932-3663B572CE5A Q35124919-DAD6E64B-770D-4165-AA38-634226CD2FA2 Q35124931-D3F2BC00-6C14-427E-8ECA-C9A235AC968D Q35124936-2A2CD0C8-1B37-47E6-86FF-3CCD32BF00DC Q35124939-771EE96D-69B6-4F0D-8501-34FC8354D0C4 Q35124958-DF05BD95-5620-4671-9E45-4A1C2945C4D0 Q35124970-13464211-B84F-4AF5-88BD-1D363B623257 Q35142189-980F56F1-4A7A-4F9A-BAAF-DA0583664B38 Q35146687-A712402C-0739-4665-B08E-14AF0AEC3C55 Q35216275-862DAAEC-1015-4397-9EC3-0B72CF7A2D86 Q35345807-D66E2C3D-2D14-4FE2-9507-92C2615C6DDD Q35589634-F7220833-5B00-4CC9-A276-441FA798AB62 Q35794099-90952B10-C45A-44D5-9C64-6C120E9957CA Q35814594-E35DD17C-B99D-411D-B992-9F9389AAE983 Q35929458-CD7A2F0B-7DD8-4006-92FF-740D70AA8E96 Q36338387-6A458105-F881-4FF8-948A-C69E0545DC39 Q36380146-FF29930A-FC2A-47C1-A5CA-43F6E3042E3D Q36506174-36410F20-347F-4144-8420-499BD8CBD754 Q36669665-61FE38EB-6F0A-46DF-B73B-97C371566918

P2860

Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study.

http://www.wikidata.org/entity/Q36875697

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Considerations in the rational ...... viral Treatment (START) study.

@en

type

label

Considerations in the rational ...... viral Treatment (START) study.

@en

prefLabel

Considerations in the rational ...... viral Treatment (START) study.

@en

P1433

Q36875697-6165FB09-320D-4F1E-A951-DB0EBEEF67F1

P1476

Q36875697-628F2438-56BB-425E-9868-FD37C6D2AAE0

P2093

Q36875697-36AD196B-23D5-41CE-B120-84D38D51B87E

Q36875697-56A5F520-C644-467D-A1B5-97495D90AE2D

Q36875697-5CFC6309-CD1D-4011-A90D-61B65FC448DE

Q36875697-8A955323-B520-46D6-932B-771320ADFB23

Q36875697-95EA2D7C-FAB5-434C-A3E9-8083B72B749E

Q36875697-9E3F4C3C-7874-41FC-B2A0-93F1826DB58A

Q36875697-A6E7760A-A670-4BD2-94FB-A3F990F7B14B

Q36875697-D7B56C14-159E-4220-9D76-03502ED96A33

Q36875697-DC022271-DFF8-4753-BEB1-0BEE28DCAC79

P2860

Q36875697-00131DE7-8D9D-40BF-BDC2-D152FD9CAF83

Q36875697-01BA4BA9-02C9-4FEE-BADF-6BC64F4B4FF9

Q36875697-06D1294C-ADE3-4646-A4C7-90E67CD34F28

Q36875697-078DD24E-6594-4936-85FE-F97AB2D85837

Q36875697-0B32809E-11D2-4099-A757-5861FA1C9E10

Q36875697-148D86BE-3BB7-4E85-9BC2-995B486BAA9C

Q36875697-151F2A84-4012-4878-AD3A-8A6AFA1007FA

Q36875697-1DFAC86F-382C-4530-88DE-40AA12DEF0F5

Q36875697-1EF14DF0-3803-4E96-AAE3-6904E516C8EF

Q36875697-207B36FD-51A7-4A4A-978D-21B9464506B4

P304

Q36875697-B10B3F7F-5C1D-410A-925F-8D9CD92F1006

P31

Q36875697-0B4EA4E7-29BE-463C-A44E-2BE3D1ABF610

P356

Q36875697-C2471850-8289-4129-B6A6-AFF34370A133

P433

Q36875697-1B1D22EE-A2D2-4E3E-B4E7-BEADAC7890ED

P478

Q36875697-419D4F28-8D44-4355-A182-30498833AAE8

P50

Q36875697-756EDF85-687C-4E43-9E4B-DDF2E9D47CA8

Q36875697-BC286AB6-22E3-42BB-BB0E-6E60900B3671

Q36875697-C6F50EFB-7DDD-4699-9116-C38A41B37C40

Q36875697-F165353C-0ABE-4F43-9399-A069E95762EA

P577

Q36875697-E08C06FD-2F38-49EC-A8D0-88640566299F

P698

Q36875697-CDE0A54A-3D10-4B33-8740-209A1382CFBC

P932

Q36875697-017F1758-E90F-4254-ABB1-6DE21D4B7E27

P356

1740774512440342

P1433

Clinical Trials

P1476

Considerations in the rational ...... viral Treatment (START) study.

@en

P2093

Abdel G Babiker

http://www.w3.org/2001/XMLSchema#string

Andrew Phillips

http://www.w3.org/2001/XMLSchema#string

Birgit Grund

http://www.w3.org/2001/XMLSchema#string

Fred M Gordin

http://www.w3.org/2001/XMLSchema#string

Giota Touloumi

http://www.w3.org/2001/XMLSchema#string

INSIGHT START Study Group

http://www.w3.org/2001/XMLSchema#string

James D Neaton

http://www.w3.org/2001/XMLSchema#string

Michael J Vjechaj

http://www.w3.org/2001/XMLSchema#string

Sarah L Pett

http://www.w3.org/2001/XMLSchema#string

P2860

Microbial translocation is a cause of systemic immune activation in chronic HIV infection

Prevention of HIV-1 infection with early antiretroviral therapy

Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

A multiple testing procedure for clinical trials

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group

CD4+ count-guided interruption of antiretroviral treatment

Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy--the CASCADE collaboration: a collaboration of 23 cohort studies.

Effect of early versus deferred antiretroviral therapy for HIV on survival.

P304

S5-S36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1740774512440342

http://www.w3.org/2001/XMLSchema#string

P433

1 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Gerd Fätkenheuer

INSIGHT START Study Group

P577

2012-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22547421

http://www.w3.org/2001/XMLSchema#string

P932

3664112

http://www.w3.org/2001/XMLSchema#string